Skip to main content
. 2021 Oct 26;11(1):9–21. doi: 10.1159/000518619

Fig. 1.

Fig. 1

a OS (any irAE vs. no irAE); (b): OS (grade ≥3 vs. grades 1–2 vs. no irAE); (c): PFS (any irAE vs. no irAE); (d): PFS (grade ≥3 vs. grades 1–2 vs. no irAE). irAE, immune-related adverse event; ICI, immune checkpoint inhibitor; OS, overall survival; PFS, progression-free survival.